{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:54:34Z","timestamp":1764305674106},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T00:00:00Z","timestamp":1555891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s11886-019-1137-5","type":"journal-article","created":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T07:02:35Z","timestamp":1555916555000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Device Closure of Patent Foramen Ovale for Cryptogenic Stroke: Patient Selection and Outcomes According to New Randomized Trials"],"prefix":"10.1007","volume":"21","author":[{"given":"Adam M.","family":"Carroll","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,22]]},"reference":[{"issue":"11","key":"1137_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMoa1009639","volume":"366","author":"AJ Furlan","year":"2012","unstructured":"Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366(11):991\u20139.","journal-title":"N Engl J Med"},{"key":"1137_CR2","doi-asserted-by":"crossref","unstructured":"Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. InMayo Clinic Proceedings 1984 Jan 1 (vol. 59, No. 1, pp. 17-20). Elsevier.","DOI":"10.1016\/S0025-6196(12)60336-X"},{"issue":"12","key":"1137_CR3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa1211716","volume":"368","author":"B Meier","year":"2013","unstructured":"Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368(12):1083\u201391.","journal-title":"N Engl J Med"},{"issue":"12","key":"1137_CR4","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa1301440","volume":"368","author":"JD Carroll","year":"2013","unstructured":"Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368(12):1092\u2013100.","journal-title":"N Engl J Med"},{"issue":"3","key":"1137_CR5","doi-asserted-by":"publisher","first-page":"e004152","DOI":"10.1161\/CIRCINTERVENTIONS.117.004152","volume":"11","author":"DM Wiktor","year":"2018","unstructured":"Wiktor DM, Carroll JD. The case for selective patent foramen ovale closure after cryptogenic Stroke. Circ Cardiovasc Interv. 2018;11(3):e004152.","journal-title":"Circ Cardiovasc Interv"},{"issue":"6","key":"1137_CR6","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1161\/STROKEAHA.117.018153","volume":"49","author":"JL Saver","year":"2018","unstructured":"Saver JL, Mattle HP, Thaler D. Patent foramen ovale closure versus medical therapy for cryptogenic ischemic stroke: a topical review. Stroke. 2018;49(6):1541\u20138.","journal-title":"Stroke."},{"issue":"11","key":"1137_CR7","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","volume":"377","author":"JL Saver","year":"2017","unstructured":"\u2022\u2022 Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377(11):1022\u201332 Multicenter RCT demonstrating superiority of PFO closure to medical therapy in preventing recurrent nonfatal stroke, fatal ischemic stroke, and\/or early death for patients with prior cryptogenic stroke.","journal-title":"N Engl J Med"},{"issue":"11","key":"1137_CR8","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","volume":"377","author":"L S\u00f8ndergaard","year":"2017","unstructured":"\u2022\u2022 S\u00f8ndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377(11):1033\u201342 Multinational trial demonstrating superiority of PFO closure combined with antiplatelet therapy relative to antiplatelet therapy alone in preventing recurrent stroke in those with prior cryptogenic stroke, but with higher rates of device complication and atrial fibrillation.","journal-title":"N Engl J Med"},{"issue":"11","key":"1137_CR9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","volume":"377","author":"JL Mas","year":"2017","unstructured":"\u2022\u2022 Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377(11):1011\u201321 Multicenter trial demonstrating superiority of PFO closure with antiplatelet therapy relative to antiplatelet therapy alone in preventing stroke recurrence in those with prior cryptogenic stroke likely caused by PFO, but with higher rates of atrial fibrillation.","journal-title":"N Engl J Med"},{"key":"1137_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/JMDH.S46890","volume":"6","author":"N Mirzada","year":"2013","unstructured":"Mirzada N, Ladenvall P, Hansson P, Eriksson P, Dellborg M. Multidisciplinary management of patent foramen ovale (PFO) and cryptogenic stroke\/TIA. J Multidiscip Healthc. 2013;6:357\u201363.","journal-title":"J Multidiscip Healthc"},{"issue":"7","key":"1137_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1212\/WNL.0b013e3182a08d59","volume":"81","author":"DM Kent","year":"2013","unstructured":"Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013;81(7):619\u201325.","journal-title":"Neurology."}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1137-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-019-1137-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1137-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T23:25:18Z","timestamp":1587425118000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-019-1137-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,22]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1137"],"URL":"https:\/\/doi.org\/10.1007\/s11886-019-1137-5","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,22]]},"assertion":[{"value":"22 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"John D. Carroll has served on the national steering committee of the RESPECT trial and has received payments for activities related to the work performed by the steering committee. These payments were from the study sponsors over the duration of the trial including AGA Medical, St. Jude Medical, and Abbott Vascular.Adam M. Carroll declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in the RESPECT trial involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"48"}}